drugset / Trial / NCT05555017

Tracer-Guided Surgery for Recurrent Prostate Cancer

NCT05555017

Phase 2 Unknown 60 enrolled The Netherlands Cancer Institute
RandomizedParallel-groupOpen-labelTreatment

Summary

ADT with or without robot-assisted PSMA-radioguided surgery for patients with recurrent prostate cancer.

Timeline

Start
2023-02-15
Primary completion
2024-11
Completion
2025-11

Drugs

EvaluationDrugModalityDoseRoute
Background Bicalutamide Other / unclassified 50 mg Oral
Background Triptorelin Other / unclassified 22.5 mg Subcutaneous

Indications